Potential role of tedizolid phosphate in the treatment of acute bacterial skin infections

References

• Dong SL Kelly KD Oland RC Holroyd BR Rowe BH ED management of cellulitis: a review of five urban centers Am J Emerg Med 2001 19 7 535 540 11698996
   PubMed Web of Science ®Google Scholar
• Centers for Disease Control and Prevention (CDC) Soft tissue infections among injection drug users – San Francisco, California, 1996–2000 MMWR Morb Mortal Wkly Rep 2001 50 19 381 384 11465906
   PubMedGoogle Scholar
• Edelsberg J Taneja C Zervos M Trends in US hospital admissions for skin and soft tissue infections Emerg Infect Dis 2009 15 9 1516 1518 19788830
   PubMed Web of Science ®Google Scholar
• Shen HN Lu CL Skin and soft tissue infections in hospitalized and critically ill patients: a nationwide population-based study BMC Infect Dis 2010 10 151 20525332
   PubMed Web of Science ®Google Scholar
• Moet GJ Jones RN Biedenbach DJ Stilwell MG Fritsche TR Contemporary causes of skin and soft tissue infections in North America, Latin America, and Europe: report from the SENTRY Antimicrobial Surveillance Program (1998–2004) Diagn Microbiol Infect Dis 2007 57 1 7 13 17059876
   PubMed Web of Science ®Google Scholar
• Moran GJ Krishnadasan A Gorwitz RJ Methicillin-resistant S. aureus infections among patients in the emergency department N Engl J Med 2006 355 7 666 674 16914702
   PubMed Web of Science ®Google Scholar
• Tenover FC Goering RV Methicillin-resistant Staphylococcus aureus strain USA300: origin and epidemiology J Antimicrob Chemother 2009 64 3 441 446 19608582
   PubMed Web of Science ®Google Scholar
• Goering RV Larsen AR Skov R Tenover FC Anderson KL Dunman PM Comparative genomic analysis of European and Middle Eastern community-associated methicillin-resistant Staphylococcus aureus (CC80:ST80-IV) isolates by high-density microarray Clin Microbiol Infect 2009 15 8 748 755 19523053
   PubMed Web of Science ®Google Scholar
• Hetem DJ Westh H Boye K Jarløv JO Bonten MJ Bootsma MC Nosocomial transmission of community-associated methicillin-resistant Staphylococcus aureus in Danish Hospitals J Antimicrob Chemother 2012 67 7 1775 1780 22523315
   PubMed Web of Science ®Google Scholar
• Landrum ML Neumann C Cook C Epidemiology of Staphylococcus aureus blood and skin and soft tissue infections in the US military health system, 2005–2010 JAMA 2012 308 1 50 59 22760291
   PubMed Web of Science ®Google Scholar
• Hiramatsu K Hanaki H Ino T Yabuta K Oguri T Tenover FC Methicillin-resistant Staphylococcus aureus clinical strain with reduced vancomycin susceptibility J Antimicrob Chemother 1997 40 1 135 136 9249217
   PubMed Web of Science ®Google Scholar
• Smith TL Pearson ML Wilcox KR Emergence of vancomycin resistance in Staphylococcus aureus. Glycopeptide-Intermediate Staphylococcus aureus Working Group N Engl J Med 1999 340 7 493 501 10021469
   PubMed Web of Science ®Google Scholar
• Centers for Disease Control and Prevention (CDC) Staphylococcus aureus resistant to vancomycin – United States, 2002 MMWR Morb Mortal Wkly Rep 2002 51 26 565 567 12139181
   PubMedGoogle Scholar
• Sievert DM Rudrik JT Patel JB McDonald LC Wilkins MJ Hageman JC Vancomycin-resistant Staphylococcus aureus in the United States, 2002–2006 Clin Infect Dis 2008 46 5 668 674 18257700
   PubMed Web of Science ®Google Scholar
• Farrell DJ Mendes RE Ross JE Sader HS Jones RN LEADER Program results for 2009: an activity and spectrum analysis of linezolid using 6,414 clinical isolates from 56 medical centers in the United States Antimicrob Agents Chemother 2011 55 8 3684 3690 21670176
   PubMed Web of Science ®Google Scholar
• Flamm RK Farrell DJ Mendes RE Ross JE Sader HS Jones RN LEADER surveillance program results for 2010: an activity and spectrum analysis of linezolid using 6801 clinical isolates from the United States (61 medical centers) Diagn Microbiol Infect Dis 2012 74 1 54 61 22704791
   PubMed Web of Science ®Google Scholar
• Kehrenberg C Schwarz S Jacobsen L Hansen LH Vester B A new mechanism for chloramphenicol, florfenicol and clindamycin resistance: methylation of 23S ribosomal RNA at A2503 Mol Microbiol 2005 57 4 1064 1073 16091044
   PubMed Web of Science ®Google Scholar
• Long KS Poehlsgaard J Kehrenberg C Schwarz S Vester B The Cfr rRNA methyltransferase confers resistance to Phenicols, Lincosamides, Oxazolidinones, Pleuromutilins, and Streptogramin A antibiotics Antimicrob Agents Chemother 2006 50 7 2500 2505 16801432
   PubMed Web of Science ®Google Scholar
• Smith LK Mankin AS Transcriptional and translational control of the mlr operon, which confers resistance to seven classes of protein synthesis inhibitors Antimicrob Agents Chemother 2008 52 5 1703 1712 18299405
   PubMed Web of Science ®Google Scholar
• Mendes RE Deshpande LM Castanheira M DiPersio J Saubolle MA Jones RN First report of cfr-mediated resistance to linezolid in human staphylococcal clinical isolates recovered in the United States Antimicrob Agents Chemother 2008 52 6 2244 2246 18391032
   PubMed Web of Science ®Google Scholar
• Toh SM Xiong L Arias CA Acquisition of a natural resistance gene renders a clinical strain of methicillin-resistant Staphylococcus aureus resistant to the synthetic antibiotic linezolid Mol Microbiol 2007 64 6 1506 1514 17555436
   PubMed Web of Science ®Google Scholar
• Cui L Tominaga E Neoh HM Hiramatsu K Correlation between Reduced Daptomycin Susceptibility and Vancomycin Resistance in Vancomycin-Intermediate Staphylococcus aureus Antimicrob Agents Chemother 2006 50 3 1079 1082 16495273
   PubMed Web of Science ®Google Scholar
• Kelley PG Gao W Ward PB Howden BP Daptomycin non-susceptibility in vancomycin-intermediate Staphylococcus aureus (VISA) and heterogeneous-VISA (hVISA): implications for therapy after vancomycin treatment failure J Antimicrob Chemother 2011 66 5 1057 1060 21393156
   PubMed Web of Science ®Google Scholar
• Miller BA Gray A Leblanc TW Sexton DJ Martin AR Slama TG Acute eosinophilic pneumonia secondary to daptomycin: a report of three cases Clin Infect Dis 2010 50 11 e63 e68 20420515
   PubMed Web of Science ®Google Scholar
• Cubicin® (daptomycin for injection) for intravenous use [prescribing information] Silver Spring, MD Food and Drug Administration (FDA) 2012 Available from: http://www.accessdata.fda.gov/drugsatfda_docs/label/2012/021572s039lbl.pdf Accessed July 7, 2012
   Google Scholar
• Morales G Picazo JJ Baos E Resistance to linezolid is mediated by the cfr gene in the first report of an outbreak of line-zolid-resistant Staphylococcus aureus Clin Infect Dis 2010 50 6 821 825 20144045
   PubMed Web of Science ®Google Scholar
• Trius Therapeutics Tedizolid phosphate (TR-701) profile [web page on the Internet] San Diego, CA Trius Therapeutics Available from: http://www.triusrx.com/trius-therapeutics-tedizolid-profile.php Accessed July 7, 2012
   Google Scholar
• Bae SK Yang SH Shin KN Rhee JK Yo o M Lee MG Pharmacokinetics of DA-7218, a new oxazolidinone, and its active metabolite, DA-7157, after intravenous and oral administration of DA-7218 and DA-7157 to rats J Pharm Pharmacol 2007 59 7 955 963 17637190
   PubMed Web of Science ®Google Scholar
• Moellering RC Linezolid: the first oxazolidinone antimicrobial Ann Intern Med 2003 138 2 135 142 12529096
   PubMed Web of Science ®Google Scholar
• Colca JR McDonald WG Waldon DJ Cross-linking in the living cell locates the site of action of oxazolidinone antibiotics J Biol Chem 2003 278 24 21972 21979 12690106
   PubMed Web of Science ®Google Scholar
• Im WB Choi SH Park JY Finn J Yoon SH Discovery of torezolid as a novel 5-hydroxymethyl-oxazolidinone antibacterial agent Eur J Med Chem 2011 46 4 1027 1039 21292356
   PubMed Web of Science ®Google Scholar
• Kim E Choi S Im W Rhee J Pharmacokinetics of TR-701 (DA-7218), a new oxazolidinone in mice, rats and dogs Poster presented at the 47th Interscience Conference on Antimicrobial Agents and Chemotherapy September 17–20, 2007 Chicago, IL
   Google Scholar
• Bien P Prokocimer P Munoz KA Bethune C Absolute bioavailability of TR-701 FA and pharmacokinetics after single and multiple dose intravenous administration in healthy adult subjects Poster presented at the 50th Interscience Conference on Antimicrobial Agents and Chemotherapy September 12–15, 2010 Boston, MA
   Google Scholar
• Louie A Liu W Kulawy R Drusano GL In vivo pharmacodynamics of torezolid phosphate (TR-701), a new oxazolidinone antibiotic, against methicillin-susceptible and methicillin-resistant Staphylococcus aureus strains in a mouse thigh infection model Antimicrob Agents Chemother 2011 55 7 3453 3460 21502615
   PubMed Web of Science ®Google Scholar
• Munoz KA Bien P Prokocimer P Bethune C Effect of food on the pharmacokinetics of torezolid (TR-700) in healthy adult subjects Poster presented at the 19th European Congress of Clinical Microbiology and Infectious Diseases May 16–19, 2009 Helsinki, Finland
   Google Scholar
• Dreskin H Boyea T Barker J Fang E Prokocimer P An evaluation of the absorption, metabolism, and excretion of orally administered [¹⁴C]-TR-701 FA in healthy subjects Poster presented at the 51st Interscience Conference on Antimicrobial Agents and Chemotherapy September 17–20, 2011 Chicago, IL
   Google Scholar
• Prokocimer P Bien P Munoz KA Bohn J Wright R Bethune C Human pharmacokinetics of the prodrug TR-701 and TR-700, its active moiety, after multiple oral doses of TR-701, a novel oxazolidinone Poster presented at the 48th Interscience Conference on Antimicrobial Agents and Chemotherapy October 25–28, 2008 Washington DC
   Google Scholar
• Bien P Munoz KA Bohn J Wright R Bethune C Prokocimer P Human pharmacokinetics of TR-700 after ascending single oral doses of the prodrug TR-701, a novel oxazolidinone antibiotic Poster presented at the 48th Interscience Conference on Antimicrobial Agents and Chemotherapy October 25–28, 2008 Washington DC
   Google Scholar
• Mondick J Gastonguay MR Bien P DeAnda C Prokocimer P Population pharmacokinetic modeling of TR-700 in patients with complicated skin and skin structure infections Poster presented at the 50th Interscience Conference on Antimicrobial Agents and Chemotherapy September 12–15, 2010 Boston, MA
   Google Scholar
• Prokocimer P Bien P Surber J Phase 2, randomized, doubleblind, dose-ranging study evaluating the safety, tolerability, population pharmacokinetics, and efficacy of oral torezolid phosphate in patients with complicated skin and skin structure infections Antimicrob Agents Chemother 2011 55 2 583 592 21115795
   PubMed Web of Science ®Google Scholar
• Housman ST Pope JS Russomanno J Pulmonary disposition of tedizolid following administration of once-daily oral 200-milligram tedizolid phosphate in healthy adult volunteers Antimicrob Agents Chemother 2012 56 5 2627 2634 22330925
   PubMed Web of Science ®Google Scholar
• Sahre M Sabarinath S Grant M Skin and soft tissue concentrations of tedizolid (formerly torezolid), a novel oxazolidinone, following a single oral dose in healthy volunteers Int J Antimicrob Agents 2012 40 1 51 54 22584101
   PubMed Web of Science ®Google Scholar
• Flanagan S Munoz KA Minassian S Improved pharmacokinetics of the novel oxazolidinone antibiotic tedizolid phosphate compared with linezolid in healthy subjects Poster presented at the American College of Clinical Pharmacy (ACCP) Annual Meeting October 20–24, 2012 Hollywood, FL
   Google Scholar
• Flanagan S Morris D Boyea T A phase 1 study of intravenously administered tedizolid phosphate in subjects with advanced renal impairment Poster presented at the 52nd Interscience Conference on Antimicrobial Agents and Chemotherapy September 9–12, 2012 San Francisco, CA
   Google Scholar
• Flanagan S Boyea T Dreskin H A phase 1 study of orally administered tedizolid phosphate in subjects with moderate or severe hepatic impairment Poster presented at the 52nd Interscience Conference on Antimicrobial Agents and Chemotherapy September 9–12, 2012 San Francisco, CA
   Google Scholar
• Dreskin H Munoz KA Fang E Safety and pharmacokinetics of single oral administration of tedizolid phosphate in healthy elderly subjects and adult control subjects Poster presented at the 52nd Interscience Conference on Antimicrobial Agents and Chemotherapy September 9–12, 2012 San Francisco, CA
   Google Scholar
• Dreskin H Munoz KA Bradley J Safety and pharmacokinetics after single oral and IV administration of tedizolid phosphate in adolescent patients Poster presented at the 52nd Interscience Conference on Antimicrobial Agents and Chemotherapy September 9–12, 2012 San Francisco, CA
   Google Scholar
• Brown SD Traczewski MM Comparative in vitro antimicrobial activities of torezolid (TR-700), the active moiety of a new oxazolidinone, torezolid phosphate (TR-701), determination of tentative disk diffusion interpretive criteria, and quality control ranges Antimicrob Agents Chemother 2010 54 5 2063 2069 20231392
   PubMed Web of Science ®Google Scholar
• Betriu C Morales G Rodríguez-Avial I Comparative activities of TR-700 (torezolid) against staphylococcal blood isolates collected in Spain Antimicrob Agents Chemother 2010 54 5 2212 2215 20176900
   PubMed Web of Science ®Google Scholar
• Schaadt R Sweeney D Shinabarger D Zurenko G In vitro activity of TR-700, the active ingredient of the antibacterial prodrug TR-701, a novel oxazolidinone antibacterial agent Antimicrob Agents Chemother 2009 53 8 3236 3239 19528279
   PubMed Web of Science ®Google Scholar
• Shaw KJ Poppe S Schaadt R In vitro activity of TR-700, the antibacterial moiety of the prodrug TR-701, against linezolid-resistant strains Antimicrob Agents Chemother 2008 52 12 4442 4447 18838596
   PubMed Web of Science ®Google Scholar
• Rodríguez-Avial I Culebras E Betriu C Morales G Pena I Picazo JJ In vitro activity of tedizolid (TR-700) against linezolid-resistant staphylococci J Antimicrob Chemother 2012 67 1 167 169 21954458
   PubMed Web of Science ®Google Scholar
• Jones RN Moet GJ Sader HS Mendes RE Castanheira M TR-700 in vitro activity against and resistance mutation frequencies among Grampositive pathogens J Antimicrob Chemother 2009 63 4 716 720 19218276
   PubMed Web of Science ®Google Scholar
• Yum JH Choi SH Yong D Comparative in vitro activities of torezolid (DA-7157) against clinical isolates of aerobic and anaerobic bacteria in South Korea Antimicrob Agents Chemother 2010 54 12 5381 5386 20837761
   PubMed Web of Science ®Google Scholar
• Prokocimer P Bien P Deanda C Pillar CM Bartizal K In vitro activity and microbiological efficacy of tedizolid (TR-700) against Gram-positive clinical isolates from a phase 2 study of oral tedizolid phosphate (TR-701) in patients with complicated skin and skin structure infections Antimicrob Agents Chemother 2012 56 9 4608 4613 22687509
   PubMed Web of Science ®Google Scholar
• Choi S Im W Bartizal K Activity of tedizolid phosphate (TR-701) in murine models of infection with penicillin-resistant and penicillinsensitive Streptococcus pneumoniae Antimicrob Agents Chemother 2012 56 9 4713 4717 22713339
   PubMed Web of Science ®Google Scholar
• Livermore DM Mushtaq S Warner M Woodford N Activity of oxazolidinone TR-700 against linezolid-susceptible and -resistant staphylococci and enterococci J Antimicrob Chemother 2009 63 4 713 715 19164418
   PubMed Web of Science ®Google Scholar
• Vera-Cabrera L Gonzalez E Rendon A In vitro activities of DA-7157 and DA-7218 against Mycobacterium tuberculosis and Nocardia brasiliensis Antimicrob Agents Chemother 9 2006 50 9 3170 3172 16940121
   PubMed Web of Science ®Google Scholar
• Gonzales RD Schreckenberger PC Graham MB Kelkar S DenBesten K Quinn J P Infections due to vancomycin-resistant Enterococcus faecium resistant to linezolid Lancet 2001 357 9263 1179 11323048
   PubMed Web of Science ®Google Scholar
• Tsiodras S Gold HS Sakoulas G Linezolid resistance in a clinical isolate of Staphylococcus aureus Lancet 2001 358 9277 207 208 11476839
   PubMed Web of Science ®Google Scholar
• Locke JB Hilgers M Shaw KJ Mutations in ribosomal protein L3 are associated with oxazolidinone resistance in staphylococci of clinical origin Antimicrob Agents Chemother 2009 53 12 5275 5278 19805557
   PubMed Web of Science ®Google Scholar
• Locke JB Morales G Hilgers M Elevated linezolid resistance in clinical cfr-positive Staphylococcus aureus isolates is associated with co-occurring mutations in ribosomal protein L3 Antimicrob Agents Chemother 2010 54 12 5352 5355 20837755
   PubMed Web of Science ®Google Scholar
• Locke JB Finn J Hilgers M Structure-activity relationships of diverse oxazolidinones for linezolid-resistant Staphylococcus aureus strains possessing the cfr methyltransferase gene or ribosomal mutations Antimicrob Agents Chemother 2010 54 12 5337 5343 20837751
   PubMed Web of Science ®Google Scholar
• Locke JB Hilgers M Shaw KJ Novel ribosomal mutations in Staphylococcus aureus strains identified through selection with the oxazolidinones linezolid and torezolid (TR-700) Antimicrob Agents Chemother 2009 53 12 5265 5274 19752277
   PubMed Web of Science ®Google Scholar
• Lemaire S Van Bambeke F Appelbaum PC Tulkens PM Cellular pharmacokinetics and intracellular activity of torezolid (TR-700): studies with human macrophage (THP-1) and endothelial (HUVEC) cell lines J Antimicrob Chemother 2009 64 5 1035 1043 19759040
   PubMed Web of Science ®Google Scholar
• Drusano GL Liu W Kulawy R Louie A Impact of granulocytes on the antimicrobial effect of tedizolid in a mouse thigh infection model Antimicrob Agents Chemother 2011 55 11 5300 5305 21911576
   PubMed Web of Science ®Google Scholar
• Keel RA Tessier PR Crandon JL Nicolau DP Comparative efficacies of human simulated exposures of tedizolid and linezolid against Staphylococcus aureus in the murine thigh infection model Antimicrob Agents Chemother 2012 56 8 4403 4407 22687504
   PubMed Web of Science ®Google Scholar
• Vera-Cabrera L Espinoza-González NA Welsh O Ocampo-Candiani J Castro-Garza J Activity of novel oxazolidinones against Nocardia brasiliensis growing within THP-1 macrophages J Antimicrob Chemother 2009 64 5 1013 1017 19710075
   PubMed Web of Science ®Google Scholar
• Espinoza-González NA Welsh O Ocampo-Candiani J Evaluation of the Combined Therapy of DA-7218, a New Oxazolidinone, and Trimethoprim/Sulfamethoxazole in the Treatment of Experimental Actinomycetoma by Nocardia brasiliensis Curr Drug Deliv 5 24 2010
   Google Scholar
• Espinoza-González NA Welsh O de Torres NW Efficacy of DA-7218, a new oxazolidinone prodrug, in the treatment of experimental actinomycetoma produced by Nocardia brasiliensis Molecules 2008 13 1 31 40 18259127
   PubMed Web of Science ®Google Scholar
• Yamaki J Synold T Wong-Beringer A Antivirulence potential of TR-700 and clindamycin on clinical isolates of Staphylococcus aureus producing phenol-soluble modulins Antimicrob Agents Chemother 2011 55 9 4432 4435 21670179
   PubMed Web of Science ®Google Scholar
• Trius Therapeutics TR-701 FA vs Linezolid for the treatment of acute bacterial skin and skin structure infections (ABSSSI) ClinicalTrials gov [website on the Internet] Bethseda, MD US National Library of Medicine 2010 [updated November 9, 2011]. Available from: http://clinicaltrials.gov/ct2/show/NCT01170221?term=tedizolid&rank=4. NLM identifier: NCT01170221Accessed July 7, 2012
   Google Scholar
• Trius Therapeutics Phase 3 clinical results: TR-701 posters and publications [web page on the Internet] San Diego, CA Trius Therapeutics Available from: http://www.triusrx.com/trius-therapeutics-tedizolid-results.php Accessed July 7, 2012
   Google Scholar
• De Anda C Fang E Das A Morillo MC Prokocimer P Comparison of tedizolid phosphate and linezolid in investigator’s assessment of clinical response in patients with cellulitis in United States and Europe from a phase 3 ABSSSI study Poster presented at the 22nd European Congress of Clinical Microbiology and Infectious Diseases March 31–April 3, 2012 London, UK
   Google Scholar
• Trius Therapeutics TR-701 FA vs linezolid for the treatment of acute bacterial skin and skin structure infections ClinicalTrials gov [website on the Internet] Bethseda, MD US National Library of Medicine 2011 [updated August 1, 2012]. Available from: http://clinicaltrials.gov/ct2/show/NCT01421511?term=tedizolid&rank=14. NLM identifier: NCT01421511Accessed January 10, 2013
   Google Scholar
• Bien P Prokocimer P Munoz KA Bohn J The safety of single ascending oral doses of TR-701, a novel oxazolidinone prodrug antibiotic Poster presented at the 19th European Congress of Clinical Microbiology and Infectious Diseases May 16–19, 2009 Helsinki, Finland
   Google Scholar
• Bradley J Arrieta A Capparelli E A phase 1, open-label, multicenter, single-dose, pharmacokinetic, safety and tolerance study of oral tedizolid phosphate in 12 to 17 year old patients Poster presented at the 22nd European Congress of Clinical Microbiology and Infectious Diseases March 31–April 3, 2012 London, UK
   Google Scholar
• Munoz KA Bien P Prokocimer P Assessment of the venous tolerability of torezolid phosphate infused via a peripheral catheter: a novel approach Poster presented at the 21st European Congress of Clinical Microbiology and Infectious Diseases May 7–10, 2011 Milan, Italy
   Google Scholar
• Trius Therapeutics A phase 2 safety and exploratory skin lesion measurement of TR-701 FA study ClinicalTrialsgov [website on the Internet] Bethseda, MD US National Library of Medicine 2012 [updated September 5, 2012]. Available from: http://clinicaltrials.gov/ct2/show/NCT01519778?term=tedizolid&rank=10. NLM identifier: NCT01519778Accessed July 7, 2012
   Google Scholar
• Gerson SL Kaplan SL Bruss JB Hematologic effects of linezolid: summary of clinical experience Antimicrob Agents Chemother 2002 46 8 2723 2726 12121967
   PubMed Web of Science ®Google Scholar
• Birmingham MC Rayner CR Meagher AK Flavin SM Batts DH Schentag JJ Linezolid for the treatment of multidrug-resistant, grampositive infections: experience from a compassionate-use program Clin Infect Dis 2003 36 2 159 168 12522747
   PubMed Web of Science ®Google Scholar
• Zyvox® (linezolid for injection, tablets, for oral suspension) [package insert] New York, NY Pfizer 2012 Available from: http://www.pfizer.com/files/products/uspi_zyvox.pdf Accessed July 7, 2012
   Google Scholar
• Kim D Chung H Choi S Im W Rhee J Single and repeated-dose toxicity of TR-701 (DA-7218) in rodents Poster presented at the 47th Interscience Conference on Antimicrobial Agents and Chemotherapy September 17–20, 2007 Chicago, IL
   Google Scholar
• Prokocimer P Bien P Munoz A Aster R Hematologic effects of TR-701, linezolid and placebo administered for 21 days in healthy subjects Poster presented at the 48th Conference on Antimicrobial Agents and Chemotherapy October 25–28, 2008 Washington DC
   Google Scholar
• Bien P Prokocimer P Munoz KA Bohn J The safety of 21-day multiple ascending oral doses of TR-701, a novel oxazolidinone prodrug antibiotic Poster presented at the 19th European Congress of Clinical Microbiology and Infectious Diseases May 16–19, 2009 Helsinki, Finland
   Google Scholar
• Javaheri M Khurana RN O’hearn TM Lai MM Sadun AA Linezolid-induced optic neuropathy: a mitochondrial disorder? Br J Ophthalmol 2007 91 1 111 115 17179125
   PubMed Web of Science ®Google Scholar
• Frippiat F Derue G Causal relationship between neuropathy and prolonged linezolid use Clin Infect Dis 2004 39 3 439 15307017
   PubMed Web of Science ®Google Scholar
• Lee E Burger S Shah J Linezolid-associated toxic optic neuropathy: a report of 2 cases Clin Infect Dis 2003 37 10 1389 1391 14583875
   PubMed Web of Science ®Google Scholar
• Trius Therapeutics A phase 1, open-label, 10 day safety study ClinicalTrialsgov [website on the Internet] Bethseda, MD US National Library of Medicine 2012 [updated December 5, 2012]. Available from: http://clinicaltrials.gov/ct2/show?term=tedizolid&rank=11. NLM identifier: NCT01623401Accessed July 7, 2012
   Google Scholar
• FDA Zyvox (linezolid): drug safety communication: serious CNS reactions possible when given to patients taking certain psychiatric medications [web page on the Internet] Silver Spring, MD FDA [updated October 21, 2011]. Available from: http://www.fda.gov/Safety/MedWatch/SafetyInformation/SafetyAlertsforHumanMedicalProducts/ucm265479.htm Accessed July 7, 2012
   Google Scholar
• Shaw KJ Barbachyn MR The oxazolidinones: past, present, and future Ann N Y Acad Sci 2011 1241 48 70 22191526
   PubMed Web of Science ®Google Scholar
• Flanagan S Minassian S Fang E Lack of MAO inhibition by tedizolid phosphate in clinical and nonclinical studies Poster presented at the 52nd Interscience Conference on Antimicrobial Agents and Chemotherapy September 9–12, 2012 San Francisco, CA
   Google Scholar
• Bae SK Chung WS Kim EJ Pharmacokinetics of DA-7867, a new oxazolidinone, after intravenous or oral administration to rats: intestinal first-pass effect Antimicrob Agents Chemother 2004 48 2 659 662 14742232
   PubMed Web of Science ®Google Scholar